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Abstract
Background: Human platelets are a rich reservoir of molecules that promote regenerative processes and
microbicidal activity. This activity might be increased by concentration in platelet-rich plasma (PRP) products and
modulated by the presence of leukocytes. Despite extensive use in clinical procedures, only few studies have
investigated PRP’s real microbicidal potential. Therefore, this study aimed at comparing the in vitro microbicidal
activity of platelets and leukocyte-enriched PRP (L-PRP) to pure platelet-rich plasma (P-PRP) and the contribution of
leukocytes to microbicidal properties.
Antimicrobial effects of P- and L-PRP were tested against Escherichia Coli, Staphylococcus Aureus, Klebsiella
Pneumoniae, Pseudomonas Aeruginosa and Enterococcus Faecalis. Furthermore, L-PRP was frozen (L-PRP cryo) to
assess whether the preparation maintained in vitro characteristics. Microbicidal proteins released by the three
preparations were also evaluated.
Results: L-PRP, L-PRP cryo and P-PRP generally induced comparable bacterial growth inhibition for up to 4 h’
incubation, range 1–4 log. MIP-1α, RANTES, GRO-α, IL-8, NAP-2, SDF-1α and IL-6 showed strong microbicidal
potential.
Conclusions: We found in vitro antibacterial activity of L-PRP and P-PRP and the possibility to cryopreserve L-PRP,
without important changes to its effectiveness; similar microbicidal activity between preparations containing or not
leukocytes; and the contribution of three new molecules (NAP-2, SDF-1α and IL-6).
Keywords: Platelet-rich plasma, Leukocytes, Bacterial growth inhibition, Antimicrobial activity, Microbicidal proteins,
Nosocomial infections
Background
Human platelets are a rich reservoir of molecules and
growth factors that can promote regenerative processes
[1, 2] and stimulate tissue healing by the local release of
platelet-derived growth factors and other bioactive mole-
cules [3–6]. In addition, platelets have been associated
with antibacterial host defense [7–10], due to the release
of platelet microbicidal proteins (PMP) [11] and multiple
chemokines that, sharing molecular structures (CC or
CXC motifs) with multiple antimicrobial peptides
(AMP), result in the double role of chemoattractant and
microbicidal proteins [12, 13].
These proteins act as a first line of defense against
invading micro-organisms and molecules released
after platelet activation are also able to recruit cells
(e.g. leukocytes), thus modulating in vivo multiple
physiological processes [8].
The antibacterial potential of platelets might be
increased through their concentration in platelet-rich
plasma (PRP) products, thus making these blood-
derivatives good candidates for preventing operative
and post-operative infections, and avoiding the risk of
immunological reactions because of their autologous
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origins. Accordingly, in recent decades various types of
PRP preparations have been developed, from pure
platelet-rich plasma (P-PRP, characterized by the presence
of platelets only) to leukocyte- and platelet-rich plasma
(L-PRP) [14, 15]. As leukocytes play an important role in
the innate host-defense, the antibacterial effects of plasma
enriched in platelets and leukocytes might have increased
microbicidal activity compared to the fractions containing
platelets alone [16].
Unfortunately, despite the extensive use of such com-
pounds in a variety of surgical and clinical procedures
[17–21], up to now only few studies have investigated
platelet microbicidal activity [22–26] and, therefore, the
real antibacterial potential of PRP. In addition, the many
protocols for PRP preparation, the possibility to include
different cellular components in various proportions and
the lack of a consensus terminology (so that different
acronyms identify similar preparations) make the de-
finition of PRP biological and antibacterial properties
difficult [15, 27, 28].
Accordingly, the purpose of the current study was to
investigate the in vitro microbicidal activity of a blood-
derivative enriched in platelets and leukocytes (called
L-PRP) compared to pure platelet-rich plasma (P-PRP),
to assess their effects and the contribution of the
leukocyte component to the antibacterial properties.
The microbicidal activities of P-PRP and L-PRP were
tested against Escherichia Coli, Staphylococcus Aureus,
Klebsiella Pneumoniae, Pseudomonas Aeruginosa and
Enterococcus Faecalis, as species potentially involved in
bone, soft tissue and wound infections [29, 30] and
representing the strains more commonly involved in
nosocomial infections.
In addition, since haemoderivatives can be used for pa-
tients treatment after collection and storage, L-PRP was
also frozen and then thawed to obtain the cryopreserved
L-PRP (L-PRP cryo), to assess whether the preparation
maintained its in vitro characteristics against the selected
bacteria.
We showed similar in vitro antibacterial activity of L-PRP
and P-PRP against the selected bacteria, and the possibility
to cryopreserve L-PRP without important changes to its
effectiveness. The contribution of three new molecules




Ten healthy men (mean age ± SD: 29.9 ± 3.4 years),
enrolled on a voluntary basis, signed a written in-
formed consent form to participate in the study protocol
which was approved by the Rizzoli Orthopedic Institute
Ethic Committee.
Subjects with smoking habits, taking non-steroidal
anti-inflammatory drugs for 5 days before blood collec-
tion, suffering from systemic disorders and/or infections,
or with hemoglobin concentrations <11 g/dl and platelet
numbers ≤ 150x103/μl, were excluded from the study.
Code numbers assigned to the samples assured subject
anonymity.
Blood-derivative preparation
P-PRP was prepared following a one-step procedure.
Briefly, 45 ml of venous blood was collected from each
subject in five tubes containing 1 ml of sodium citrate
solution (3.8 %) as anticoagulant and centrifuged at
460 g for 8 min [31, 32], thus obtaining three layers:
platelet-poor plasma (PPP) on the top of the tube, P-PRP
in the middle and erythrocytes at the bottom of the tubes.
In sterile conditions, about 1 ml/tube of P-PRP, located on
the red blood cell pellet, was carefully harvested avoiding
leukocyte collection.
L-PRP was prepared following a two-step procedure.
Briefly, 150 ml of venous blood was collected from each
subject in a sterile plastic bag containing 21 ml of
citrate-phosphate-dextrose as anti-coagulant. After a
first centrifugation step at 730 g for 15 min to separate
erythrocytes, the fraction located on the red blood cell
pellet was transferred in a second bag via a closed circuit
and underwent a second centrifugation at 3800 g for
10 min, thus obtaining two separate layers: platelet-
poor plasma (PPP), on the top of the bag and L-PRP
(a concentrate of platelets and leukocytes) at the bot-
tom. In sterile conditions, the L-PRP fraction was
carefully harvested [32]. One aliquot of L-PRP was
frozen at −30 °C for 2 h and then thawed thus obtain-
ing the cryopreserved fraction (L-PRP cryo).
Activation of platelet concentrates
Two aliquots of P-PRP, L-PRP and L-PRP cryo from
each donor were activated by the addition of 10 %
calcium chloride (CaCl2, final concentration: 22,8 mM)
and incubated for 1 h and 18 h at 37 °C in 5 % CO2, cor-
responding, respectively, to the first and last time-point
of bacterial incubation. After incubation, PRP samples
were centrifuged (15 min at 2800 g at 20 °C) and super-
natants were collected and frozen at -30C° until use.
Quantification of microbicidal proteins release
For the evaluation of microbicidal proteins, P-PRP, L-PRP
and L-PRP-cryo from each donor were assayed in duplicate.
Commercially available multiplex bead-based sandwich
immunoassay kits were used to simultaneously evaluate
the following soluble factors: Macrophage Inflammatory
Protein (MIP)-1α (CCL3), Regulated on Activation Normal
T Expressed and Secreted protein (RANTES) (CCL5),
GRO-α (CXCL1), Interleukin (IL)-8 (CXCL8), Interleukin
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(IL)-6 (Bio-Rad Laboratories, CA, USA); neutrophil-
activating protein (NAP)-2 (CXCL7), stromal cell-derived
factor (SDF)-1α (CXCL12) (Milliplex MAP Kit, Millipore,
Bedford, MA), as previously described [33, 34]. Briefly,
distinct sets of fluorescently dyed beads loaded with capture
monoclonal antibodies, specific for each cytokine to be
tested, were used. Samples or standards (diluted according
to the manufacturer’s recommendations) or standards
(50 μl/well) were incubated with 50 μl of pre-mixed bead
sets inside the wells of a 96-well microtiter plate.
The formation of different sandwich immune complexes
on distinct bead sets was measured and quantified by using
the Bio-Plex Protein Array System (Bio-Rad Laboratories,
USA). A 50 μl volume was sampled by each well and the
fluorescent signal of a minimum of 50 beads per region
(chemokine/cytokine) was evaluated and recorded. Values
with a coefficient of variation above the 10 % were dis-
carded before the final data analysis.
Data were analyzed by the Bio-Plex Manager software
version 6.0 (Bio-Rad Laboratories, USA). Standard levels
between 70 and 130 % of the expected values were consid-
ered to be accurate and were used. In general, at least six
standards were accepted and used to establish standard
curves following a Five-Parameter Logistic (5-PL) regres-
sion model. Sample concentrations were immediately inter-
polated from the standard curves.
Determination of platelet and leukocyte numbers
Platelet and leukocyte count was performed by the
Coulter LH 750 (Beckman Coulter Inc. Miami, Fl, USA)
automated hematology analyzer. Linearity was 5–1000 ×
103/μl for platelet count and 0.1-100 × 103/μl for white
blood cell count.
The median platelet number was 861x103/μl (interquar-
tile range 715-959 × 103/μl) in L-PRP; 290 × 103/μl (inter-
quartile range 182–385 × 103/μl) in P-PRP; 275.5 × 103/μl
(interquartile range 207-484 × 103/μl) in L-PRP cryo.
The median leukocyte count was <0.2 × 103/μl in P-PRP;
5.450 × 103/μl (interquartile range 5.050-6.425 × 103/μl) in
L-PRP; 0.550 × 103/μl (interquartile range 0.425-1.275 ×
103/μl) in L-PRP cryo.
Preparation of bacterial stocks
Bacterial species were obtained from the Bioresource
Collection of the American Type Culture Collection
(ATCC, Manassas, VA, USA), chosen according to mor-
phological characteristics of membrane and growth [35]
and as species implicated in bone and soft-tissue infec-
tions [29, 30].
Three Gram negative (Escherichia coli, ATCC 25922;
Pseudomonas aeruginosa ATCC 27853; Klebsiella
pneumoniae ATCC 700603) and two Gram positive
(Staphylococcus aureus, ATCC 29213 and Enterococcus
faecalis, ATCC 29212) bacterial strains were selected.
From a starting suspension of 108 colony-forming
units (CFU)/ml in Tryptic Soy Broth medium (TSB,
MEUS S.R.L., Italy), 10-fold serial dilutions (106, 105
and 104 CFU/ml) were prepared, thus obtaining bac-
terial concentrations mirroring a localized infection
in vivo [23, 36].
Plating assay and bacterial count
In sterile conditions, P-PRP, L-PRP and L-PRP cryo
(90 μl), obtained from each donor were activated with
10 μl of CaCl2 (22.8 mM final concentration) and added
to 900 μl of each bacterial dilution to be tested (104, 105,
106 CFU/ml). Tubes were mixed vigorously and then
incubated at 37 °C for 1, 2, 4 and 18 h respectively. TSB
was used as control condition.
After incubation, 10 μl of each bacterial suspension was
spread on Blood Horse Agar (MEUS S.R.L., Italy) using a
seeding distributed in 3 quadrants with an appendix in
terminal part (Fig. 1). Agar plates were incubated at 37 °C
for 18–24 h, then a semi quantitative estimation of bacterial
growth (CFU/ml) was performed by counting the colonies
in each quadrant (Table 1).
Statistical analysis
Values are presented as medians, interquartile ranges
and percentage, as appropriate.
The antimicrobial activity is calculated as difference
between experimental conditions and control culture
conditions and reported as log of growth inhibition.
Data are expressed as percent frequency of subject
displaying a certain inhibition.
Fig. 1 Plating pattern. a 1st quadrant; b 2nd quadrant; c 3rd quadrant;
d appendix. (Source: OpenWetWare.org)
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Differences in growth inhibition among incubation
times, types of treatment and number of seeded bacteria
were analyzed using the Friedman-Anova test. Differences
between two culture conditions were analyzed by the
Wilcoxon-matched pair test.
Correlations between concentrations of released soluble
factors and the growth inhibition of each bacterium strain
at the different time points were analyzed by means of the
Kendall-Tau rank correlation test.
The level of statistical significance was set at p < 0.05
and adjusted according to Bonferroni’s correction for
multiple comparisons (p < 0.017), as appropriate. Data




In general, bacterial growth inhibition produced by the
three PRP preparations lasted for up to 4 h of incuba-
tion, and ranged between 1 and 4 log (corresponding to
inhibitions from 10 to 10.000 CFU/ml), depending on
the bacterium and the experimental conditions tested.
After 18 h, no growth inhibitions were observed.
Escherichia coli (Fig. 2a-i) showed significant growth
inhibitions after treatment with L-PRP, L-PRP cryo or
P-PRP for up to 4 h when 104 and 105 CFU/ml
were seeded (Friedman-Anova test: p < 0.05, at least)
(Fig. 2a, b, d, e, g, h), but not at 106 CFU/ml (Fig. 2c,
f, i). Whatever the PRP preparation, at 104 CFU/ml a
decreasing inhibiting effect was observed between 1
and 4 h of incubation (Fig. 2a, d, g) and between 2 and
4 h only with L-PRP cryo (Fig. 2d). When increasing
the concentration of bacteria, the growth inhibition
was similar independently of the incubation time.
Decreased growth inhibitions were also observed with
increasing bacterial concentrations after 1 h on the same
preparation (Friedman-Anova test: p < 0.05, at least)
(Fig. 2a-c; d-f; g-i). This decrease was particularly evident
between 104 (Fig. 2a, c) and 106 CFU/ml (Fig. 2g, i), fol-
lowing incubation with L- and P-PRP. No significant dif-
ferences were observed among the preparations.
Staphylococcus aureus (Fig. 3) was significantly
inhibited for at least up to 4 h, independently of the
preparation tested or the number of seeded bacteria
(Friedman-Anova test: p < 0.01, at least) (Fig. 3a-i). For
almost all the experimental conditions, the inhibition of
growth was similar during the first two hours of incuba-
tion (Fig. 3a-h), whereas it decreased between 1 and 4 h
(Fig. 3a, c-i) and between 2 and 4 h (Fig. 3a-i), excluding
105 CFU/ml bacteria treated with L-PRP (Fig. 3b). Inde-
pendently of the preparation, increasing concentrations
of bacteria underwent similar inhibitions of growth
when incubated for the same time.
L-PRP, L-PRP cryo and P-PRP induced similar growth
inhibitions at 104 and 105 CFU/ml (Fig. 3a, d, g and
b, e, h) for each incubation time, whereas significant dif-
ferences were observed at 106 CFU/ml (Friedman-Anova
test: p < 0.02, at least) (Fig. 3c, f, i).
Klebsiella pneumoniae did not show significant time-
dependent growth inhibition within each preparation
for up to 4 h whatever the concentration of seeded
bacteria (Fig. 4a-h), excluded P-PRP at 106 CFU/ml
(Friedman-Anova test: p < 0.02) (Fig. 4i). Within each
preparation, different growth inhibitions were ob-
served among the three bacterial concentrations after
1, 2 and 4 h with L-PRP (Fig. 4a-c), after 2 and 4 h
with L-PRP cryo (Fig. 4d-f ) and after 1 and 2 h
with P-PRP (Friedman-Anova test: p < 0.05, at least)
(Fig. 4g-i). Significant differences were also observed
comparing the preparations after 1 and 2 h when seed-
ing 104 CFU/ml (Fig. 4a, d, g), but only after 1 h at
higher bacterial concentrations (Fig. 4b, e, h and c, f, i)
(Friedman-Anova test: p < 0.05).
Pseudomonas aeruginosa showed significant growth
inhibition with time, when 104 (Fig. 5a, d, g) and
105 CFU/ml (Fig. 5b, e, h) were seeded (Friedman-Anova
test: p < 0.01, at least), independently of the preparations.
Growth inhibition differences were observed between 1
(Fig. 5a, b, d) and 4 h of incubation (Fig. 5e, g, h) and
between 2 and 4 h (Fig. 5b, e, g). No growth differences
were found when 106 CFU/ml were seeded (Fig. 5c, f, i).
After incubation with L-PRP and L-PRP cryo, similar
growth inhibitions were observed among the bacterial
concentrations on the same time, whereas a significant
decrease was found after 2 h of incubation with P-PRP
(Friedman-Anova test: p < 0.05) (Fig. 5g-i). No significant
differences of growth inhibition were observed among
the preparations.
Enterococcus faecalis growth was inhibited by all the
preparations for up to 4 h of incubation, whatever the
bacterial concentrations tested (Friedman-Anova test:
p < 0.01, at least) (Fig. 6a-i). Differences were observed
between 1 and 4 h when 104 CFU/ml were seeded with
L-PRP cryo and P-PRP (Fig. 6d, g); at 105 CFU/ml
with L-PRP and P-PRP (Fig. 6b, h) and at 106 CFU/ml
Table 1 Semi-quantitative estimation of bacterial growth
(CFU/ml)
Number of quadrant Colony count
1st quadrant 0 1-4 ≥5 ≥5 ≥5 ≥5
2nd quadrant <5 ≥5 ≥5 ≥5
3rd quadrant <5 ≥5 ≥5
Appendix 0 ≥1
Approximate growth (CFU/ml) <103 103 104 105 106 >106
Bacterial growth was determined by the number of colonies detected on each
agar plate
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with all the preparations (Fig. 6c, f, i). Moreover, differ-
ences of growth inhibition were observed between 1 and
2 h when 104 CFU/ml were seeded with P-PRP (Fig. 6g)
and when 106 CFU/ml were incubated with L-PRP cryo
and P-PRP (Fig. 6f, i). Between 2 and 4 h, inhibition was
evident at 105 CFU/ml incubated with L-PRP and
P-PRP (Wilcoxon-matched pair test: p < 0.01, at least)
(Fig. 6b, h) and at 106 CFU/ml incubated with P-PRP
(Wilcoxon-matched pair test: p < 0.001) (Fig. 6i). Inde-
pendently of the preparation, significant variations among
the different bacterial concentrations were found after 2
and 4 h of incubation with L-PRP and L-PRP cryo and
only after 4 h with P-PRP (Friedman-Anova test: p < 0.05,
at least) (Fig. 6a-c, d-f and g-i), with significant differences
between 105 and 106 CFU/ml after 2 h of incubation with
L-PRP cryo (Fig. 6 e, f). The comparison among the three
plasma fractions evidenced a decreasing inhibiting activity
(from L-PRP to P-PRP) following the incubation of
105 CFU/ml at 2 h (Friedman-Anova test: p < 0.05)
(Fig. 6b, e, h).
Microbicidal protein evaluation
The concentrations of the main soluble factors, described
as microbicidal proteins, were different among the three
PRP preparations (as determined by Friedman-Anova test:
Fig. 2 Escherichia coli growth inhibition. Each bacterial dilution to be tested (104, 105, 106 CFU/ml, as reported above each panel) was incubated
with L-PRP, L-PRP cryo and P-PRP at 37 °C for 1, 2, 4 h. Then each bacterial suspension was spread on Blood Horse Agar plates and incubated at
37 °C for 18–24 h. A semi quantitative estimation of bacterial growth (CFU/ml) was performed by counting the colonies in each plate quadrant
(for details see Methods). The antimicrobial activity was calculated as difference between experimental conditions and control culture conditions and
expressed as growth inhibition: 1log, 2log, 3log and 4log growth inhibition indicate a decrease of 10, 100, 1000 and 10000 CFU/ml respectively
compared to CFU/ml indicated above each panel. Data are reported as percentage of subjects (Frequency %) displaying a certain inhibition. Growth
inhibition differences among incubation times, within equal PRP preparations and bacterial concentrations. Friedman-Anova test: a) p < 0.0005;
b, e) p < 0.05; d) p < 0.0002; g) p < 0.005; h) p < 0.02; c, f, i) not significant. Wilcoxon-matched pair test: as reported in the figure. Growth inhibition
differences among bacterial concentrations, within equal incubation times and PRP preparations. Friedman-Anova test: 1 h a) vs b) vs c) and g) vs h)
vs i) p < 0.01; d) vs e) vs f) p < 0.05; 2 h and 4 h, not significant. Wilcoxon-matched pair test: 1 h a) vs c) and g) vs i) p < 0.01. Growth inhibition
differences among PRP preparations within equal bacterial concentrations and incubation times. Friedman-Anova test: not significant
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p < 0.02, at least) (Fig. 7a-d, g), excluded NAP-2 and
SDF-1α (Fig. 7e, f ), whose concentrations were similar.
In general, the molecules were more concentrated in
L-PRP (MIP-1α, RANTES, GRO-α, IL-8 and IL-6) and
in L-PRP cryo (RANTES, GRO-α, IL-8 and IL-6) than in
P-PRP (Wilcoxon-matched pair test: p < 0.02 at least).
The concentrations of RANTES, GRO-α and IL-8 were
stable after cryopreservation, whereas they were slightly
decreased in MIP-1α and IL-6 (Wilcoxon-matched pair
test: p < 0.02), as determined by the comparison between
L-PRP and L-PRP cryo.
After 18 h of activation, IL-8, RANTES and GRO-α
concentrations increased in all the preparations, whereas
NAP-2 and SDF-1α were stable (data not shown). IL-6
concentration increased only in L-PRP and L-PRP cryo,
whereas MIP-1α increased in L-PRP and P-PRP, but not
L-PRP cryo (data not shown).
For all the bacteria, we evaluated the correlation be-
tween bacterial growth inhibition (induced by the three
PRP preparations obtained by each donor after 1, 2 and
4 h of incubation) and the concentration of microbicidal
proteins released by the matched PRP preparations after
1 h of activation (Table 2). It was not possible to analyze
the corresponding correlations after 18 h, since the bac-
teria reached an overgrowth phase.
The concentrations of the molecules considered (MIP-1α/
CCL3, RANTES/CCL5, GRO-α/CXCL1, NAP-2/CXCL7,
IL-8/CXCL8, SDF-1α/CXCL12 and IL-6) were strongly
Fig. 3 Staphylococcus aureus growth inhibition. Each bacterial dilution to be tested (104, 105, 106 CFU/ml, as reported above each panel) was
incubated with L-PRP, L-PRP cryo and P-PRP at 37 °C for 1, 2, 4 h. Then each bacterial suspension was spread on Blood Horse Agar plates and
incubated at 37 °C for 18–24 h. A semi quantitative estimation of bacterial growth (CFU/ml) was performed by counting the colonies in each
plate quadrant (for details see Methods). The antimicrobial activity was calculated as difference between experimental conditions and control
culture conditions and expressed as growth inhibition: 1log, 2log, 3log and 4log growth inhibition indicate a decrease of 10, 100, 1000 and
10000 CFU/ml respectively compared to CFU/ml indicated above each panel. Data are reported as percentage of subjects (Frequency %) displaying a
certain inhibition. Growth inhibition differences among incubation times, within equal PRP preparations and bacterial concentrations. Friedman-Anova
test: a, c, f) p < 0.0002; b) p < 0.01; d, e, g) p < 0.0005; h) p < 0.001; i) p < 0.0001. Wilcoxon-matched pair test: as reported in the figure. Growth inhibition
differences among bacterial concentrations, within equal incubation times and PRP preparations. Friedman-Anova test: not significant. Growth inhibition
differences among PRP preparations within equal bacterial concentrations and incubation times. Friedman-Anova test: c) vs f) vs i) 1 h p < 0.002; 2 h
p < 0.02; 4 h p < 0.01. Wilcoxon-matched pair test: not significant
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correlated to bacterial growth inhibition, mainly from the
second hour of incubation (Table 2).
Escherichia coli inhibition showed correlations with
RANTES, GRO-α and SDF-1α concentrations (Kendall-
Tau rank correlation: p < 0.05, at least). Staphylococcus
aureus inhibition correlated with the concentrations of
all the molecules excluded IL-6 (Kendall-Tau rank
correlation: p < 0.05, at least), whereas Klebsiella pneu-
moniae, Pseudomonas aeruginosa and Enterococcus fae-
calis inhibition correlated with the concentrations of
all the microbicidal molecules considered (Kendall-Tau
rank correlation: p < 0.05, at least).
Discussion
In this study, the antibacterial activity of L-PRP
(leukocyte and platelet-rich plasma) and P-PRP (pure
platelet-rich plasma) was evaluated against five bacteria
strains (Escherichia coli, Staphylococcus aureus, Klebsiella
pneumoniae, Pseudomonas aeruginosa, Enterococcus
faecalis). The contribution of leukocytes and the preser-
vation of the biological properties after freezing were also
evaluated.
We found a time-dependent inhibition of bacteria
growth, for up to 4 h, at low bacterial numbers in
Escherichia coli and Pseudomonas aeruginosa and at
Fig. 4 Klebsiella pneumoniae growth inhibition. Each bacterial dilution to be tested (104, 105, 106 CFU/ml, as reported above each panel) was
incubated with L-PRP, L-PRP cryo and P-PRP at 37 °C for 1, 2, 4 h. Then each bacterial suspension was spread on Blood Horse Agar plates and
incubated at 37 °C for 18–24 h. A semi quantitative estimation of bacterial growth (CFU/ml) was performed by counting the colonies in each
plate quadrant (for details see Methods). The antimicrobial activity was calculated as difference between experimental conditions and control
culture conditions and expressed as growth inhibition: 1log, 2log, 3log and 4log growth inhibition indicate a decrease of 10, 100, 1000 and
10000 CFU/ml respectively compared to CFU/ml indicated above each panel. Data are reported as percentage of subjects (Frequency %) displaying a
certain inhibition. Growth inhibition differences among incubation times, within equal PRP preparations and bacterial concentrations. Friedman-Anova
test: a-h) not significant; i) p < 0.02. Wilcoxon-matched pair test: not significant. Growth inhibition differences among bacterial concentrations, within
equal incubation times and PRP preparations. Friedman-Anova test: 1 h a) vs b) vs c) and g) vs h) vs i) p < 0.05; d) vs e) vs f) not significant; 2 h
a) vs b) vs c) and g) vs h) vs i) p < 0.01; d) vs e) vs f) p < 0.05; 4 h a) vs b) vs c) p < 0.01; d) vs e) vs f) p < 0.05; g) vs h) vs i) not significant. Wilcoxon-
matched pair test: 2 h g) vs i) p < 0.01. Growth inhibition differences among PRP preparations within equal bacterial concentrations and incubation
times. Friedman-Anova test: a) vs d) vs g) 1 h p < 0.02; 2 h p < 0.05; b) vs e) vs h) 1 h p < 0.05; c) vs f) vs i) 1 h p < 0.05. Wilcoxon-matched pair test:
not significant
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higher numbers in Staphylococcus aureus and Enterococcus
faecalis, after treatment with the three plasma fractions
(L-PRP, L-PRP cryo or P-PRP). Klebsiella pneumoniae
was the only strain not showing a time-dependent in-
hibition of growth whatever bacterial concentration
and PRP preparation.
The loss of antibacterial effect displayed by all the
preparations after 18 h suggests a short-term and not
complete microbicidal activity at the experimental con-
centrations tested, and/or that the amount of microbici-
dal proteins present in PRP preparation is not sufficient
to limit the bacteria growth for a long time, which gives
important indications for the early prophylactic use of
PRP in the clinical practice.
Previous data have shown that analogous PRP formu-
lations, enriched in leukocytes, had similar antimicrobial
effects against Escherichia coli [22, 25], Staphylococcus
aureus [22–24] and Pseudomonas aeruginosa [25],
whereas the data concerning Klebsiella pneumoniae
are not univocal, thus indicating both partial [25] and
lack of susceptibility [22].
The analysis of the distribution of growth inhibitions (as
indicated by log values) identified Staphylococcus aureus
and Klebsiella pneumoniae as the most susceptible bac-
teria, which underwent a decrease of 10.000 CFU/ml (4
logarithms of growth inhibition) in various experimental
conditions. Since these two strains are well-known for
their strong resistance to antibiotics [37, 38], the present
Fig. 5 Pseudomonas aeruginosa growth inhibition. Each bacterial dilution to be tested (104, 105, 106 CFU/ml, as reported above each panel) was
incubated with L-PRP, L-PRP cryo and P-PRP at 37 °C for 1, 2, 4 h. Then each bacterial suspension was spread on Blood Horse Agar plates and
incubated at 37 °C for 18–24 h. A semi quantitative estimation of bacterial growth (CFU/ml) was performed by counting the colonies in each
plate quadrant (for details see Methods). The antimicrobial activity was calculated as difference between experimental conditions and control
culture conditions and expressed as growth inhibition: 1log, 2log, 3log and 4log growth inhibition indicate a decrease of 10, 100, 1000 and
10000 CFU/ml respectively compared to CFU/ml indicated above each panel. Data are reported as percentage of subjects (Frequency %) displaying a
certain inhibition. Growth inhibition differences among incubation times, within equal PRP preparations and bacterial concentrations. Friedman-Anova
test: a) p < 0.01; b, e) p < 0.001; d, h) p < 0.002; g) p < 0.0005; c, f, i) not significant. Wilcoxon-matched pair test: as reported in the figure. Growth
inhibition differences among bacterial concentrations, within equal incubation times and PRP preparations. Friedman-Anova test: 1 h and 4 h for
all the PRP preparations, not significant; 2 h g) vs h) vs i) p < 0.05; a) vs b) vs c) and d) vs e) vs f) not significant. Wilcoxon-matched pair test: not
significant. Growth inhibition differences among PRP preparations within equal bacterial concentrations and incubation times. Friedman-Anova test:
not significant
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results are particularly relevant for the early prophylaxis
against possible bacterial contaminations during clinical
applications of PRP.
The similar microbicidal activity displayed by both
L-PRP and L-PRP cryo, against all the strains considered,
demonstrated the maintenance of the antimicrobial prop-
erties of L-PRP even after freezing and opens the possi-
bility for cryopreserving this preparation. PRP containing
only platelets was found to maintain coagulation ability,
platelet morphology, P-selectin expression and growth
factor release after some hours at room temperature [39].
The cryopreservability for up to 3 months of the main
proteins involved in ocular surface healing [40] and their
potential use as an alternative to fetal bovine serum for
the cryo-preservation of human mesenchymal stem cells
[41] were also reported. Furthermore, it was recently
described that the freeze-thawing storage procedure did
not affect the anabolic effects on different cell types [17].
To our knowledge, this is the first description of the
preservation of microbicidal properties following freez-
ing and these data are of particular interest, considering
the possibility of a single preparation of self-derived
platelet products to be used in consecutive administra-
tions for therapeutic purposes.
Fig. 6 Enterococcus faecalis growth inhibition. Each bacterial dilution to be tested (104, 105, 106 CFU/ml, as reported above each panel) was
incubated with L-PRP, L-PRP cryo and P-PRP at 37 °C for 1, 2, 4 h. Then each bacterial suspension was spread on Blood Horse Agar plates and
incubated at 37 °C for 18–24 h. A semi quantitative estimation of bacterial growth (CFU/ml) was performed by counting the colonies in each
plate quadrant (for details see Methods). The antimicrobial activity was calculated as difference between experimental conditions and control
culture conditions and expressed as growth inhibition: 1log, 2log, 3log and 4log growth inhibition indicate a decrease of 10, 100, 1000 and
10000 CFU/ml respectively compared to CFU/ml indicated above each panel. Data are reported as percentage of subjects (Frequency %) displaying a
certain inhibition. Growth inhibition differences among incubation times, within equal PRP preparations and bacterial concentrations. Friedman-Anova
test: a, d) p < 0.01; b, c) p < 0.001; e) p < 0.002; f, g) p < 0.0005; h, i) p < 0.0001. Wilcoxon-matched pair test: as reported in the figure. Growth inhibition
differences among bacterial concentrations, within equal incubation times and PRP preparations. Friedman-Anova test: 2 h a) vs b) vs c) p < 0.005;
d) vs e) vs f) p < 0.001; g) vs h) vs i) not significant; 4 h a) vs b) vs c) p < 0.05; d) vs e) vs f) p < 0.02; g) vs h) vs i) p < 0.05; 1 h not significant. Wilcoxon-
matched pair test: 2 h e) vs f) p < 0.005. Growth inhibition differences among PRP preparations within equal bacterial concentrations and incubation
times. Friedman-Anova test: b) vs e) vs h) 2 h p < 0.05. Wilcoxon-matched pair test: not significant
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The inclusion and the possible role played by leuko-
cytes in different PRP preparations have been variously
debated during the last decades. Previous studies have
shown mixed results, some reporting that concentrated
delivery of leukocytes to a site of injury may amplify the
release of anabolic and pro-inflammatory mediators [42],
whereas others sustaining that leukocytes enhance the
release of growth factors and anti-inflammatory media-
tors, thus possibly playing an important antibacterial
role. Indeed, although leukocytes have been proposed as
an additional source for cytokines, microbicidal proteins
and myeloperoxidase activity [43], nowadays the few
available published data do not support the increased
microbicidal activity of PRP due to the leukocyte com-
ponent [22–24]. In particular, no correlation between
microbicidal activity and the number of either platelets
or leukocytes in PRP preparations used against the
same strains we tested and between myeloperoxidase ac-
tivity and bacterial killing of PRP preparations against
Staphylococcus aureus were observed [22, 23]. Further-
more, two PRP products, containing or lacking the
leukocyte component, showed similar antimicrobial
activities [24]. In agreement, we found that the bacterial
growth inhibition was similar among the three plasma
fractions, thus strongly suggesting that the presence of
leukocytes does not supply a substantial improvement in
the antibacterial potential in PRP, with the main effects
probably due to platelet microbicidal molecules.
Considering this aspect, we evaluated the correlation
between bacterial growth inhibition and the concentration
of some soluble factors displaying microbicidal activity
[12, 13]. Among these, MIP-1α, RANTES, GRO-α, IL-8,
NAP-2 and SDF-1α are the most common, with molecular
structures of classical chemokines and therefore called
“kinocidins”, for their dual role as chemokines and micro-
bicidal effectors [8, 13].
We obtained interesting results concerning further corre-
lations among Escherichia coli, Klebsiella pneumoniae and
Fig. 7 Microbicidal protein concentrations in L-PRP, L-PRP cryo and P-PRP after 1 h of incubation. Results are expressed as medians and interquartile
ranges. Friedman-Anova test: a, b) p < 0.01; c, d) p < 0.0005; g) p < 0.001; e, f) n.s. Wilcoxon-matched pair test: as reported in the figure
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Pseudomonas aeruginosa growth inhibition and MIP-1α,
RANTES, GRO-α and IL-8 concentrations compared to
previous preliminary data on a pure-PRP preparation [44].
Moreover, a new molecule (SDF-1α), previously not
evaluated [44], showed correlations with Escherichia
coli growth inhibition. In different in vitro experiments,
strong antimicrobial effects against Escherichia coli
were found for GRO-α but not for RANTES, although
the authors used recombinant peptides at micromolar
concentrations [12]. Native chemokine concentrations
in serum are basically in the picomolar to nanomolar
range [45], as we detected in plasma concentrates,
therefore a lack of concordance with results proposed
by Yang [12] might be attributable to the use of syn-
thetic proteins instead of native molecules. In addition,
since we detected significant differences of RANTES
concentrations among the three PRP preparations, the
lack of correlation observed with Escherichia coli inhib-
ition [44] suggests the need for a threshold level for
RANTES to be effective as microbicidal protein. More-
over, as this chemokine possesses chemotactic activity
in vivo, we can speculate a microbicidal loop in which
the presence of RANTES in injected PRP directly
inhibits Escherichia coli growth and simultaneously
amplifies the response by attracting and recruiting leu-
kocytes into the sites of inflammation.
MIP-1α, RANTES and GRO-α concentrations were con-
firmed to correlate with growth inhibition of Staphylococ-
cus aureus, Pseudomonas aeruginosa and Enterococcus
faecalis [44]. In addition, we found that MIP-1α, RANTES,
GRO-α and IL-8 were involved in the inhibition of
Klebsiella pneumoniae, whereas IL-8 was involved in
the inhibition of Pseudomonas aeruginosa. All these
chemokines showed concentrations increasing from
P-PRP to L-PRP, therefore suggesting a concentration-
dependent effect of these factors on bacterial growth
inhibition.
Three new molecules (NAP-2, SDF-1α and IL-6)
considered displayed strong correlations with growth
inhibition of almost all the bacterial analyzed.
The neutrophil-activating peptide (NAP)-2 is a deriva-
tive of platelet basic protein (PBP), which is itself part of
the platelet microbicidal proteins (PMPs). NAP-2 is also
well-known as activator of neutrophils (activity shared
with the homologous IL-8 and GRO-α chemokines).
After platelet activation, NAP-2 is released and processed
at the N-terminal part, finally reaching the active form as
neutrophil activating peptide (NAP-2) [46]. During infec-
tions, proteolytic activation of NAP-2 and neutrophil at-
traction lead to an amplified response, resulting in bacterial
killing [47].
SDF (stromal cell-derived growth factor)-1α is a small
chemokine, usually induced after stimulus with lipopoly-
saccharide (a large molecule contained in the Gram
negative cell wall bacteria) [48]. SDF-1α is involved in
chemotaxis and is also considered to be the main chemo
attractant factor for the stem cells [49]. Its modulation
was proposed to be a useful therapeutic strategy for the
stimulation of tissue repair. The present results, showing
correlations between SDF-1α concentrations and the
growth inhibition of all the bacteria tested, open the possi-
bility to consider this molecule as an important component
Table 2 Correlations between bacterial growth inhibition and soluble factors
Bacteria Time Soluble factors
CCL3/MIP-1α CCL-5/RANTES CXCL1/GRO-α CXCL-8/IL-8 CXCL-7/NAP2 CXCL-12/SDF-1α IL-6
Escherichia coli 1 h - - - - - - - - - - - - - - - p < 0.05 - - -
2 h - - - p < 0.05 p < 0.05 - - - - - - p < 0.005 - - -
4 h - - - - - - p < 0.01 - - - - - - - - - - - -
Staphylococcus aureus 1 h p < 0.01 - - - p < 0.0001 - - - p < 0.01 - - - - - -
2 h p < 0.005 p < 0.01 - - - p < 0.01 p < 0.000005 p < 0.05 - - -
4 h p < 0.005 p < 0.05 - - - p < 0.01 p < 0.00001 - - - - - -
Klebsiella pneumoniae 1 h - - - p < 0.000005 p < 0.01 p < 0.01 p < 0.001 p < 0.0001 p < 0.01
2 h p < 0.01 - - - - - - - - - - - - - - - - - -
4 h p < 0.01 p < 0.05 - - - p < 0.005 p < 0.000005 p < 0.001 p < 0.005
Pseudomonas aeruginosa 1 h - - - - - - - - - - - - - - - - - - - - -
2 h p < 0.000005 p < 0.0005 p < 0.01 p < 0.000005 p < 0.005 p < 0.0001
4 h p < 0.0005 p < 0.0005 p < 0.05 p < 0.005 p < 0.000005 p < 0.001 p < 0.0005
Enterococcus faecalis 1 h - - - - - - - - - - - - p < 0.005 - - - - - -
2 h p < 0.000005 p < 0.00005 p < 0.05 p < 0.001 p < 0.0005 p < 0.00005 p < 0.000005
4 h p < 0.05 - - - - - - - - - - - - - - - - - -
Significant correlations between bacterial growth inhibition at different time points and the concentration of soluble factors released by the PRP preparations
after 1 h of activation and described with antimicrobial potential, as determined by Kendall-Tau rank correlation test
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within PRP preparations, thus displaying a double role both
as prophylactic molecule against invading microorganisms
and regulator of stem cell mobilization and therefore tissue
remodeling, considering the clinical use of PRP.
IL-6 is a cytokine, secreted by macrophages and T cells
[50], thus displaying an important role in host defense
and possibly during infections associated to antibiotic
resistant microorganisms, such as Klebsiella pneumoniae
and Enterococcus faecalis. In fact, it has been demon-
strated that IL-6 is involved in resistance to Streptococcus
pneumoniae infection in a mouse model and the knockout
of the IL-6 gene, inducing an increase in the levels of pro-
inflammatory (TNFα, IL-1β, IFN-γ) and ant-inflammatory
(IL-10) cytokines [51], resulted in the mouse’s premature
death. Although the mechanisms by which IL-6 contrib-
utes to antibacterial activity are still not clear, the role of
IL-6 against infection is commonly acknowledged [52].
Results presented in the present study, showing a
strong correlation between IL-6 concentrations and
Klebsiella pneumoniae, Pseudomonas aeruginosa and
Enterococcus faecalis growth inhibition, support the role
of IL-6 against bacterial infections.
Conclusions
In conclusion, we have shown the in vitro antibacterial
activity of L-PRP and P-PRP against five different bac-
terial strains and the possibility to cryopreserve L-PRP,
without important changes in its effectiveness, thus
allowing a single preparation to be used for multiple
in vivo administrations. Furthermore, we did not find
significant differences in microbicidal activity between
preparations containing leukocytes before and after stor-
age conditions, thus highlighting potential clinical uses for
therapeutic protocols, including soft tissue and orthopedic
surgery, or for the prevention of local infections.
The prevalent role of MIP-1α, RANTES, GRO-α and
IL-8 as mediators of bacterial inhibition was confirmed.
In addition, the microbicidal contribution in vitro of
three new molecules (NAP-2, SDF-1α and IL-6) was
highlighted.
Results in the present study supply basic information
about the most common molecules recognized as micro-
bicidal effectors and released by platelets and leukocytes
during immunological responses, however there are ob-
vious limitations compared to in vivo conditions, where
a complexity of physiological networks and molecular
mechanisms take place. Indeed, the initial in loco anti-
microbial activity of some platelet-stored and leukocyte-
derived chemokines contained in PRP, may be supported
by the chemotactic recruitment of specific cellular popu-
lations and their interaction might amplify different
prophylactic responses against infection agents and trig-
ger specific immunological pathways.
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